BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours

César Serrano, Sara Simonetti, Javier Hernández-Losa, Claudia Valverde, Cristina Carrato, Silvia Bagué, Ruth Orellana, Rosa Somoza, Teresa Moliné, Joan Carles, Pere Huguet, Cleofé Romagosa, Santiago Ramón y Cajal

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)


Aims: Benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumours occur either sporadically or are related to neurofibromatosis (NF). The mechanisms involved are well known in NF-related tumours, but still remain unclear in sporadic cases. Somatic BRAF and KRAS mutations represent the most frequent genetic events in melanocytic neoplastic lesions. Because melanocytes and Schwann cells both derive from neural crest cells, we hypothesized that BRAF and KRAS mutations might influence BPNST and MPNST development. Methods and results: BRAF exon 15 and KRAS exons 2 and 3 polymerase chain reaction (PCR) sequencing was performed in formalin-fixed/paraffin-embedded samples of 99 BPNST and MPNST, related and non-related to NF types 1 and 2. Oncogenic BRAF V600E mutations were found in four of 40 schwannomas (including one acoustic neuroma) and one of 13 MPNST, not associated with NF. A KRAS G12S mutation was also evident in one sporadic schwannoma. Conclusion: Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an important event in a subset of peripheral nerve sheath tumours not related to NF. © 2012 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)499-504
Issue number3
Publication statusPublished - 1 Feb 2013


  • Acoustic neuroma
  • BRAF
  • KRAS
  • Malignant peripheral nerve sheath tumour
  • Neurofibroma
  • Neurofibromatosis type 1
  • Neurofibromatosis type 2
  • NF1
  • NF2
  • Schwannoma


Dive into the research topics of 'BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours'. Together they form a unique fingerprint.

Cite this